SCHEMBL30563273

SCHEMBL30563273

C[C@H](NC(=O)CN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 2/20 0.44
BMP1 P13497 2/20 0.43
PTGS1 P23219 1/20 0.40
GSTK1 Q9Y2Q3 1/20 0.40
EGFR P00533 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
PTGS2 P35354 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
REN P00797 1/20 0.35
ECE1 P42892 1/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34
NMT2 O60551 1/20 0.33
NMT1 P30419 1/20 0.33
MME P08473 1/20 0.33
ACE P12821 1/20 0.33
CPA1 P15085 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8494001 0.89 GLO1 (0.49) GLO1BMP1PTGS1GSTK1ALDH1A1
SCHEMBL2804512 0.89 GLO1 (0.49) GLO1BMP1PTGS1GSTK1ALDH1A1
SCHEMBL29575827 0.86 ECE1 (0.41) GLO1PTGS1GSTK1EGFRALDH1A1
SCHEMBL30170524 0.86 GLO1 (0.44) GLO1BMP1PTGS1GSTK1EGFR
SCHEMBL30170441 0.86 GLO1 (0.44) GLO1BMP1PTGS1GSTK1EGFR
SCHEMBL4300867 0.85 NOD1 (0.44) BMP1ECE1DPP4DPP8DPP9
SCHEMBL31670609 0.85 BMP1 (0.41) GLO1BMP1PTGS1GSTK1NOD1
SCHEMBL29630368 0.84 GLO1 (0.44) GLO1BMP1PTGS1GSTK1EGFR
SCHEMBL30259507 0.83 TSHR (0.40) GLO1PTGS1GSTK1ALDH1A1LMNA
SCHEMBL13347740 0.83 GLO1 (0.43) GLO1BMP1PTGS1GSTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12257323-B2 Modified wound dressings CONVATEC TECHNOLOGIES INC. (US) 2025-03-25 US disclosed
US-20240123091-A1 MODIFIED WOUND DRESSINGS CONVATEC TECHNOLOGIES, INC. 2024-04-18 US disclosed
US-11865192-B2 Modified wound dressings CONVATEC TECHNOLOGIES, INC. (US) 2024-01-09 US disclosed
EP-3436012-B1 MODIFIED WOUND DRESSINGS CONVATEC TECHNOLOGIES INC (US) 2023-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240123091-A1 MODIFIED WOUND DRESSINGS MMP8, CD68, ELANE GLO1 14/4885BMP1 1248/4885PTGS1 272/4885
US-11865192-B2 Modified wound dressings MMP8, CD68, ELANE GLO1 14/4885BMP1 1248/4885PTGS1 272/4885
US-12257323-B2 Modified wound dressings MMP8, CD68, ELANE GLO1 14/4885BMP1 1248/4885PTGS1 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.